Question:
For the last quarter of 2017, are there any additional drugs with pass-through status?
Answer:
Effective October 1, 2017, the Centers for Medicare & Medicaid Services (CMS) granted outpatient prospective payment system  pass-through status to the four drugs below:
C9491 | Injection, avelumab, 10 mg |
C9492 | Injection, durvalumab, 10 mg |
C9493 | Injection, edaravone, 1 mg |
C9494 | Injection, ocrelizumab, 1 mg |